Clear Street initiated coverage of Rapt Therapeutics (RAPT) with a Buy rating and $3 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- RAPT Therapeutics Faces Nasdaq Delisting Notice
- Rapt Therapeutics price target lowered to $1 from $2 at UBS
- Rapt Therapeutics assumed with a Buy at H.C. Wainwright
- RAPT Therapeutics: Promising Clinical Developments and Strong Financial Performance Justify Buy Rating
- RAPT Therapeutics Reports Improved Q1 2025 Results